SciSparc Total Long-Term Assets 2017-2024 | SPRC

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

SciSparc total long-term assets from 2017 to 2024. Total long-term assets can be defined as the sum of all assets classified as non-current

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

SciSparc total long-term assets from 2017 to 2024. Total long-term assets can be defined as the sum of all assets classified as non-current

Related Stocks
Company Name	Market Cap
Chugai Pharmaceutical (CHGCY)	$70.5B
Zoetis (ZTS)	$69.4B
Takeda Pharmaceutical (TAK)	$49.4B
Daiichi Sankyo, - (DSNKY)	$48.3B
BeOne Medicines - (ONC)	$34.4B
Sandoz Group AG (SDZNY)	$27.6B
Summit Therapeutics (SMMT)	$19.5B
Merck (MKKGY)	$17B
Shionogi (SGIOY)	$14.9B
United Therapeutics (UTHR)	$14.1B
Neurocrine Biosciences (NBIX)	$13.4B
IPSEN (IPSEY)	$11.4B
Orion OYJ (ORINY)	$11.3B
Eisai (ESAIY)	$9.3B
Madrigal Pharmaceuticals (MDGL)	$9.2B
Corcept Therapeutics (CORT)	$7.4B
Grifols, S.A (GRFS)	$7B
Stevanato Group S.p.A (STVN)	$6.9B
Ionis Pharmaceuticals (IONS)	$6.8B
Ono Pharmaceutical (OPHLF)	$5.7B
Hikma Pharmaceuticals Plc (HKMPF)	$5.4B
Soleno Therapeutics (SLNO)	$3.6B
Procaps Group, S.A (PROCF)	$3.2B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$3B
Crinetics Pharmaceuticals (CRNX)	$2.9B
NewAmsterdam Pharma (NAMS)	$2.8B
Catalyst Pharmaceuticals (CPRX)	$2.6B
Hypermarcas (HYPMY)	$2.5B
Centessa Pharmaceuticals (CNTA)	$2.3B
Ocular Therapeutix (OCUL)	$2.1B